Claims of the Application

1-28. (Cancelled)

28. A compound of the formula (I),

$$Ar_1 - Y - A - (CH_2)_m - R^6$$

$$R^6 - (CH_2)_m - COOR^7$$

$$R^6 - (CH_2)_m - COOR^7$$

$$R^6 - (CH_2)_m - COOR^7$$

their derivatives, their stereoisomers, their pharmaceutically acceptable salts and their pharmaceutically acceptable compositions;

wherein Ar₁ represents a unsubstituted or substituted monocyclic or polycyclic aromatic or partially saturated aromatic polycyclic structure, which may optionally contain up to 3 heteroatoms selected from N, S or O, such as

which when substituted may have up to 4 substituents that may be identical or different, wherein said substituents selected from halo, nitro, alkyl, hydroxy, hydroxyalkyl, alkoxy, thioalkoxy, oxo, aryl, -NR¹R², -OCONR¹R², NR¹COOR², -NR¹COR², -NR¹SO₂R², NR¹CONR¹R², -OSO₂R³, -SO₂R³,

R¹ and R² independently represent hydrogen, or optionally substituted groups selected from alkyl, alkenyl, alkynyl, cylcoalkyl, heterocyclyl, aryl, heteroaryl; R³ independently represents hydrogen, or optionally substituted groups selected from alkyl, alkenyl, alkynyl, cylcoalkyl, heterocyclyl, aryl, heteroaryl, wherein said substitutents on

R¹, R² and R³ are selected from hydrogen, halo, nitro, amino, mono or di substituted amino, hydroxy, alkoxy, carboxy, cyano, alkyl, cycloalkyl, alkoxy, haloalkoxy, haloalkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl;

m and n independently represents an integer from 0 to 6;

A represents O, S or a bond;

Y is selected from $(CH_2)_p$, $(CH_2)_pB(CH_2)_q$, $(CH_2)_rB(CH_2)_pD(CH_2)_q$, wherein p, q and r each independently represents an integer from 0 to 6; B and D independently represents S, O, NR^4 or a bond, R^4 represents hydrogen, alkyl, alkenyl, $-S(O)_2-R^8$ or $-C(O)R^8$, R^8 is alkyl, alkoxy; with the proviso that when B and D represents a hetero atom p is not zero;

R⁵ and R⁶ independently represents hydrogen, alkyl, cycloalkyl or alkoxy; R⁵ and R⁶ together may form 3-8 membered cyclic ring which may optionally contains one or two hetero atoms selected from O, S or N;

R⁷ represents hydrogen, substituted or unsubstituted alkyl, cycloalkyl, alkenyl or alkynyl; wherein said substitutents are selected from hydrogen, halo, nitro, amino, mono or di substituted amino, hydroxy, alkoxy, carboxy, cyano, alkyl, cycloalkyl, alkoxy, haloalkoxy, haloalkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl.

29. A compound of formula (Ia) according to claimed 28

wherein all of the symbols are as defined above.

30. The compound of claim 29, wherein Ar_1 is substituted with $-OSO_2R^3$, and R^3 is alkyl or aryl.

| Structure | IUPAC Name |
|-----------------|---|
| O SO H OME | (S)-Ethyl 2-methoxy-3- [4-{6-methanesulfonyloxynapth-2-ylmethylamino} phenyl] propanoate |
| O S O H | Ethyl 2-ethoxy-3- [4-{6-methanesulfonyloxynapth-2-ylmethylamino} phenyl] propanoate |
| O S O H | Ethyl 2-ethoxy-5- [4-{6-methanesulfonyloxynapth-2-ylmethylamino} phenyl] pentanoate |
| ONE NO HI OME | (S)-2-methoxy-3- [4-{6- methanesulfonyloxynapth-2- ylmethylamino} phenyl] propanoic acid |
| O.S.O.H. | 2-ethoxy-3- [4-{6-methanesulfonyloxynapth-2-ylmethylamino} phenyl] propanoic acid |
| O. O. O. H. OEt | 2-Ethoxy-5- [4-{6- methanesulfonyloxynapth-2- ylmethylamino} phenyl] pentatonic acid |

| Structure | IUPAC Name |
|---|---|
| O N O O O O O O O O O O O O O O O O O O | Ethyl 2-ethoxy-3- [4-{(6-methanesulfonyloxy-1, 2, 3, 4-tetrahydronapth-2-yl) methylamino} phenyl] propanoate |
| O. S. O. H. OEt | Ethyl 2-ethoxy-3- [4-{3-(6-methane sulfonyloxy-1, 2, 3, 4-tetrahydronapth-2-yl) propylamino} phenyl] propanoate |
| O S O H | 2-ethoxy-3- [4-{(6-methanesulfonyloxy-1, 2, 3, 4-tetrahydronapth-2-yl) methylamino} phenyl] propanoic acid |
| O. S. O. H. OEt | 2-ethoxy-3- [4-{3-(6-methanesulfonyloxy-1, 2, 3, 4-tetrahydronapth-2-yl) propylamino} phenyl] propanoic aci |
| N OEt | Ethyl 2-ethoxy-3- [4-{3-(1,2,3,4-tetrahydroquinolyn-1-yl) propylamino} phenyl] propanoate |
| COOH | 2-ethoxy-3- [4-{3-(1, 2, 3, 4-tetrahydroquinolyn-1-yl) propylamino} phenyl] propanoic acid |

| Structure | IUPAC Name |
|--------------------------|---|
| CO ₂ Et | Ethyl 2-ethoxy-3- [4-{3-(indol-1-yl) propyl amino} phenyl] propanoate |
| COOMe | (S)-Methyl 2-methoxy-3- [4-{3- (indol-1-yl) propylamino} phenyl] propanoate |
| CO ₂ H | 2-ethoxy-3- [4-{3-(indol-1-yl) propyl amino} phenyl] propanoic acid |
| CO ₂ H OMe | (S)-2-methoxy-3- [4-{3-(indol-1-yl) propyl amino} phenyl] propanoic acid |
| CO ₂ Et | Ethyl 2-ethoxy-3- [4-{3-(2, 3-dihydroindol-1-yl) propylamino} phenyl] propanoate |
| CO ₂ H | 2-ethoxy-3- [4-{3-(2, 3-dihydroindol-1-yl) propylamino} phenyl] propanoic acid |

| Structure | IUPAC Name |
|-------------------------------|---|
| Me, s, O CO ₂ Et | (S)-Ethyl-2-ethoxy-3- [4-{3-(5-methanesulfonyloxyindol-1-yl) propylamino} phenyl] propanoate |
| Me s O CO ₂ Me OMe | S)-Methyl-2-methoxy-3- [4-{3-(5-methanesulfonyloxyindol-1-yl) propylamino} phenyl] propanoate |
| Me S O CO₂Me N H OEt | (S)-Methyl 3-ethoxy-4- [4-{3-(5-methanesulfonyloxyindol-1-yl) propylamino} phenyl] butanoate |
| Me s O CO ₂ H | (S)-2-ethoxy-3- [4-{3-(5-methanesulfonyloxyindol-1-yl) propylamino} phenyl] propanoic acid |
| Me S O CO ₂ H | S)-2-methoxy-3- [4-{3-(5-methanesulfonyloxyindol-1-yl) propylamino} phenyl] propanoic acid |
| Me SO O CO ₂ H | S)-3-ethoxy-4- [4-{3-(5-methanesulfonyloxyindol-1-yl) propylamino} phenyl] butanoic acid |

| Structure | IUPAC Name |
|---|--|
| Structure CO2H NH2 NH2 CO2H NH2 CO2H NH2 CO2H NH2 CO2H NH2 CO2H NH2 CO2H NH2 | (S)-2-methoxy-3- [4-{6-methanesulfonyloxynapth-2-ylmethylamino} phenyl] propanoic acid Arginine salt 2-Ethoxy-5- [4-{6-methanesulfonyloxynapth-2-ylmethylamino} phenyl] pentatonic acid Arginine salt |
| OEt | 2-ethoxy-3- [4-{(6-methanesulfonyloxy-1, 2, 3, 4-tetrahydronapth-2-yl) methylamino} phenyl] propanoic acid Arginine salt |
| O. S. O. H. H. OEI | 2-ethoxy-3- [4-{3-(6-methanesulfonyloxy-1, 2,3,4-tetrahydronapth-2-yl) propylamino} phenyl] propanoic acid Arginine salt |
| CO ₂ H NH ₂ NH ₂ NH ₂ NH ₂ | 2-ethoxy-3- [4-{3-(1, 2, 3, 4-tetrahydroquinolyn-1-yl) propylamino} phenyl] propanoic acid Arginine salt |

| Structure | IUPAC Name |
|---|--|
| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | 2-ethoxy-3- [4-{3-(indol-1-yl) propyl amino} phenyl] propanoic acid Arginine salt |
| CO ₂ H ₂ N H CO ₂ H NH ₂ NH ₂ | (S)-2-methoxy-3- [4-{3-(indol-1-yl) propyl amino} phenyl] propanoic acid Arginine salt |
| Me, s, O, O CO ₂ H (CO ₂ H (NH ₂ N (N | (S)-2-ethoxy-3- [4-{3-(5-methanesulfonyl oxyindol-1-yl) propylamino} phenyl] propanoic acid Arginine salt |
| Me, s, O O'S O | (S)-2-methoxy-3- [4-{3-(5-methanesulfonyl oxyindol-1-yl) propylamino} phenyl] propanoic acid Arginine salt |
| Me_s, O CO2H OF O OF | (S)-3-ethoxy-4- [4-{3-(5-methanesulfonyloxyindol-1-yl) propylamino} phenyl] butanoic acid Arginine salt |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | 2-ethoxy-3- [4-{3-(2,3-dihydroindol-1-yl) propylamino} phenyl] propanoic acid Arginine salt |

37. The compound of formula (Ib) according to claimed 28,

wherein all of the symbols are as defined above.

- 38. The compound of claim 37 wherein Ar_1 is substituted with $-OSO_2R^3$, and R^3 is alkyl or aryl.
- 39. The compound of formula (Ib) as claimed in claim 37 is selected from,

| Structure | IUPAC Name |
|--------------------------------|---|
| O, SO H | Ethyl 2-methyl-2- [4-{6-methanesulfonyloxynapth-2-ylmethylamino} phenoxy] propanoate |
| Me s O CO ₂ Et | Ethyl 2-methyl-2- [4-{3-(5-methanesulfonyloxyindol-1-yl) propylamino} phenoxy] propanoate |
| O, SO H | 2-methyl-2- [4-{6- methanesulfonyloxynapth-2- ylmethylamino} phenoxy] propanoic acid |
| Me, s, O, O, CO ₂ H | 2-methyl-2- [4-{3-(5-methanesulfonyloxyindol-1-yl) propylamino} phenoxy] propanoic acid |

40. The compound of formula (Ic) according to claim 28

wherein all of the symbols are as defined above.

- 41. The compound of claim 40, wherein Ar_1 is substituted with $-OSO_2R^3$, wherein R^3 is alkyl or aryl.
- 42. The compound of formula (Id) according to claim 28,

wherein all of the symbols are as defined above.

43. The compound of claim 42, wherein " Ar_1 " is substituted with $-OSO_2R^3$, where R^3 is alkyl or aryl.

44. A compound of formula (Id) according to claim 28 which is selected from:

| Structure | IUPAC Name |
|--------------------------------|---|
| O. S.O. CO ₂ Et | Ethyl 2-methyl-2- [4-{6- methanesulfonyloxynapth-2- ylmethoxy} phenoxy] propanoate |
| о, s. о — о — о — о — соон | 2-methyl-2- [4-{6- methanesulfonyloxynapth-2- ylmethoxy} phenoxy] propanoic acid |
| Me's O | Ethyl 2-methyl-2- [4-{3-(5-methanesulfonyloxyindol-1-yl) propyloxy} phenoxy] propanoate |
| Me, s, O, O, CO ₂ H | 2-methyl-2- [4-{3-(5-methanesulfonyloxyindol-1-yl) propyloxy} phenoxy] propanoic acid |

45. A compound of formula (Id) according to claim 28 which is selected from:

| Structure | IUPAC Name |
|------------------------|--|
| MsO CO ₂ Et | Ethyl 2-methyl-2-[4-{3-(4- methanesulfonyloxyphenoxy) propyloxy} phenoxy] propanoate |
| MsOOOCO_2E1 | Ethyl 2-methyl-2-[3-{3-(3- methanesulfonyloxyphenoxy) propyloxy} phenoxy] propanoate |
| MsO CO ₂ H | 2-Methyl-2-[4-{3-(4- methanesulfonyloxyphenoxy) propyloxy} phenoxy] propanoic acid |

| MsO 0 0 0 CO ₂ H | 2-Methyl-2-[3-{3-(3- methanesulfonyloxyphenoxy) propyloxy}phenoxy]propanoic acid |
|-----------------------------|--|
| MsO CO ₂ Et | Ethyl 2-methyl-2-[3-{3-(4-methanesulfonyloxyphenoxy) propyloxy} phenoxy] propanoate |
| MsO CO ₂ H | 2-Methyl-2-[3-{3-(4-methanesulfonyloxyphenoxy) propyloxy} phenoxy] propanoic acid |

46. A compound of formula (Id) according to claim 28 which is selected from:

| Structure | IUPAC Name |
|--------------------------|---|
| a O a O a Coret | Ethyl 2-methyl-2-[3-{3-(4-(paratoluenesulfonyloxy)phenoxy)propyloxy} phenoxy]propanoate |
| | |
| | Ethyl 2-methyl-2-[4-{3-(4-methanesulfonyloxyphenoxy)propyloxy}phenoxy]butanoate |
| O, SO CO ₂ Et | 1 10 52 (2 (4 (|
| 0 0 0 0 COvH | 2-methyl-2-[3-{3-(4-(para-toluenesulfonyloxy)phenoxy)propyloxy}phenoxy]propanoic acid |
| | |
| | 2-Methyl-2-[4-{3-(4-methanesulfonyloxyphenoxy)propyloxy}phenoxy]butanoic acid |
| O S O CO ₂ H | |

47. A compound of formula (Id) according to claim 28 which is selected from:

| Structure | IUPAC Name |
|--|---|
| Me, s, O, | 2-methyl-2- [4-{3-(5-methanesulfonyloxyindol-1-yl) propyloxy} phenoxy] propanoic acid Arginine salt |
| 0, s, o, | 2-Methyl-2-[4-{3-(4-methanesulfonyloxyphenoxy) propyloxy} phenoxy] propanoic acid Arginine salt |
| Me, s, O O O O O O O O O O O O O O O O O O | 2-Methyl-2-[3-{3-(3-methanesulfonyloxyphenoxy) propyloxy} phenoxy] propanoic acid Arginine salt |
| H ₂ N | 2-Methyl-2-[3-{3-(4- methanesulfonyloxyphenoxy) propyloxy} phenoxy] propanoic acid Arginine salt |
| H ₂ N ₂ H ₃ N ₄ COOH NH ₂ NH ₂ COOH NH ₂ O NH ₂ COOH | 2-Methyl-2-[3-{3-(4-(para-toluenesulfonyloxy)phenoxy)propyloxy}phenoxy]propanoic acid, arginine salt |
| 0, 5,0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | 2-Methyl-2-[4-{3-(4-methanesulfonyloxyphenoxy)propyloxy}phenoxy]butanoic acid, arginine salt |

48. The compound of formula (Ie) according to claim 1, which is

$$(CH_2)_p$$
 $(CH_2)_m$ $(CH_2)_m$ $(1e)$

wherein all of the symbols are as defined above.

- 49. The compound of claim 48, wherein Ar₁ is substituted with -OSO₂R³, and R³ is alkyl or aryl.
- 50. The compound of formula (If) according to claim 1, which is,

$$(CH_2)_p$$
 O $(CH_2)_m$ R^6 $COOR^7$ (1f)

wherein all of the symbols are as defined above.

- 51. The compound of claim 15, wherein Ar₁ is substituted with -OSO₂R³, where R³ is selected from optionally substituted groups selected from alkyl or aryl.
- 52. The compound of formula (Ie) as claimed in claim 1 is selected from:

| Structure | IUPAC Name |
|----------------------------|--|
| Me s. o Co ₂ Et | Ethyl 2-methyl-2- [4-{3-(5-methanesulfonyloxyindol-1-yl) propyl} phenoxy] propanoate |

| | To 110 54 (0 (5 |
|--|--|
| Me, s, o COOH | 2-methyl-2- [4-{3-(5-methanesulfonyloxyindol-1-yl) propyl} phenoxy] propanoic acid |
| Me's O | Ethyl 2-methyl-2- [3-{3-(5-methanesulfonyloxyindol-1-yl) propyl} phenoxy] propanoate |
| Me, s, O | 2-methyl-2- [3-{3-(5-methanesulfonyloxyindol-1-yl) propyl} phenoxy] propanoic acid |
| Me, s, O, O, CO ₂ Et | Ethyl 2-[3-{3-(5- methanesulfonyloxyindol-1-yl) propyl}phenoxy] propanoate |
| Me s. O CO ₂ H | 2-Methyl-2-[4-{4-(5- methanesulfonyloxyindol- lyl)butyl}phenoxy]propanoic acid |
| Me, s.O O'S'O N O CO ₂ H | 2-[3-{3-(5- Methanesulfonyloxyindol-1- yl)propyl}phenoxy]propanoic acid |
| 0's 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | 2-Methyl-2-[3-{3-(5-(para-toluenesulfonyloxy)indol-1-yl)propyl}phenoxy] propanoic acid |
| O'S O CO ₂ E1 | Ethyl 2-methyl-2-[3-{3-(5-(para-toluenesulfonyloxy)indol-1-yl)propyl}phenoxy] propanoate |

| Structure | TUPAC Name |
|---|--|
| Me s o o o o o o o o o o o o o o o o o o | 1-[4-{3-(5- methanesulfonyloxyindol-1- yl)propyl}phenoxy]cyclopentane-1- carboxylic acid, methyl ester |
| Me's O | 1-[4-{4-(5- methanesulfonyloxyindol-1- yl)butyl}phenoxy]cyclopentane-1- carboxylic acid, methyl ester |
| Me, s, O O O O O O O O O O O O O O O O O O | 1-[4-{3-(7-Methanesulfonyloxy-3, 4-dihydro-2 <i>H</i> -bezo [<i>b</i>] [1, 4] oxazin- 4-yl)propyl}phenoxy]cyclopentane- 1-carboxylic acid, methyl ester |
| Me s O CO ₂ H | 1-[4-{3-(5- Methanesulfonyloxyindol-1- yl)propyl}phenoxy]cyclopentane-1- carboxylic acid |
| Me s O O O CO ₂ H | 1-[4-{3-(5-methanesulfonyloxyindol-1-yl)propyl}phenoxy]cyclohexane-1-carboxylic acid |
| Me, s, O CO ₂ H | 1-[4-{4-(5- methanesulfonyloxyindol-1- yl)butyl}phenoxy]cyclopentane-1- carboxylic acid |
| Me, s, o, | 1-[4-{3-(5- Methanesulfonyloxyindol-1- yl)propyl}phenoxy]cyclohexane-1- carboxylic acid, methyl ester |

| Structure | IUPAC Name |
|-----------------------------|---|
| Me-s'O-N COOCH3 | (+) Methyl (R)-2-methyl-2-[4-{3-(5-methanesulfonyloxyindol-1-yl)propyl}phenoxy] butanoate |
| Me-s' O COOCH3 | (-) Methyl (S)-2-methyl-2-[4-{3-(5-methanesulfonyloxyindol-1-yl)propyl}phenoxy] butanoate |
| Me, s, O CO ₂ Et | Ethyl 2-methyl-2-[4-{4-(5-methanesulfonyloxyindol-1-yl)butyl}phenoxy]propanoate |
| Me-s-0 COOH | (R)- (+)-2-methyl-2-[4-{3-(5-methanesulfonyloxyindol-1-yl) propyl} phenoxy] butanoic acid |
| Me-s'-0 N O COOH | (S)- (-)-2-methyl-2-[4-{3-(5-methanesulfonyloxyindol-1-yl)propyl}phenoxy] butanoic acid |

| Structure | IUPAC Name |
|--------------------------|--|
| MsO CO ₂ Et | Ethyl 2-methyl-2-[4-{3-(3-methanesulfonyloxyphenoxy) propyl} phenoxy] propanoate |
| MsO O CO ₂ Et | Ethyl 2-methyl-2-[3-{3-(4-methanesulfonyloxyphenoxy) propyl} phenoxy] propanoate |

| MsO O CO ₂ H | 2-Methyl-2-[4-{3-(3-methanesulfonyloxyphenoxy) propyl} phenoxy] propanoic acid |
|--|--|
| MsO O CO₂H | 2-Methyl-2-[3-{3-(4-methanesulfonyloxyphenoxy) propyl} phenoxy] propanoic acid |
| O, S,O CO₂H | 2-Methyl-2-[4-{4-(4- methanesulfonyloxyphenoxy) butyl}phenoxy]propanoic acid |
| О, S.O О О О О О О О О О О О О О О О О О О О | 2-Methyl-2-[3-{5-(4-methanesulfonyloxyphenoxy)pentyl} phenoxy]propanoic acid |

| Structure | IUPAC Name |
|---|--|
| O ₂ N CO ₂ Et | Ethyl 2-methyl-2-[3-{5-(4- nitrophenoxy)propyl}phenoxy]propa noate |
| H ₂ N CO ₂ Et | Ethyl 2-methyl-2-[3-{5-(4-aminophenoxy)propyl}phenoxy]propanoate |
| John Coart | 2-Methyl-2-[4-{3-(4-(tert-butyloxycarbonylamino)phenoxy)propyl}phenoxy]propanoic acid |
| ON SON ON CO2H | 2-Methyl-2-[4-{3-(4- (methanesulfonylamino)phenoxy)pr opyl}phenoxy]propanoic acid |
| → on the contraction of the con | Ethyl 2-methyl-2-[4-{3-(4-(tert-butyloxycarbonylamino)phenoxy)propyl} opyl} phenoxy]propanoate |

| ON CO2Et | Ethyl 2-methyl-2-[4-{4-(4-methanesulfonyloxyphenoxy)butyl} phenoxy]propanoate |
|-------------------|---|
| O, SO O O O CO2EI | Ethyl 2-methyl-2-[3-{5-(4-methanesulfonyloxyphenoxy)pentyl} phenoxy]propanoate |
| O, S, O N | Ethyl 2-methyl-2-[4-{3-(4- (methanesulfonylamino)phenoxy)pr opyl}phenoxy]propanoate |

| Structure | IUPAC Name |
|--|--|
| | Ethyl 2-methyl-2- [4-{3-(3, 4-dihydro-2H-bezo [b] [1, 4] 0xazin-4-yl) propyl} phenoxy] propanoate |
| COOH | 2-methyl-2- [4-{3-(3, 4-dihydro-2H-bezo [b] [1, 4] 0xazin-4-yl) propyl} phenoxy] propanoic acid |
| H ₃ C, S, O O O O O O O O O O O O O O O O O O | Ethyl-2-methyl-2-[3-{3-(7-Methanesulfonyloxy-3, 4-dihydro-2 <i>H</i> -bezo [<i>b</i>] [1, 4] oxazin-4-yl) propyl} phenoxy] propanoate. |
| Me s O O O O CO2Et | Ethyl 2-methyl-2-[4-{4-(7-methanesulfonyloxy-3, 4-dihydro-2 <i>H</i> -bezo [<i>b</i>] [1, 4] oxazin-3-on-4-yl)butyl}phenoxy]propanoate |
| H ₃ C, O O O O O O O O O O O O O O O O O O O | 2-Methyl-2-[3-{3-(7- Methanesulfonyloxy-3, 4-dihydro- 2H-bezo [b] [1, 4] oxazin-4-yl) propyl} phenoxy] propanoic acid |

| Me, s, O O O O O O O O O O O O O O O O O O | 1-[4-{3-(7-Methanesulfonyloxy-3, 4-dihydro-2 <i>H</i> -bezo [<i>b</i>] [1, 4] oxazin- 4-yl)propyl}phenoxy] cyclopentane- 1-carboxylic acid |
|--|---|
| Me, s, O O O CO ₂ H | 2-Methyl-2-[4-{4-(7-methanesulfonyloxy-3, 4-dihydro-2 <i>H</i> -bezo [<i>b</i>] [1, 4] oxazin-3-on-4-yl)butyl}phenoxy]propanoic acid |

| Structure | IUPAC Name |
|--|--|
| Me-stood Mary Coool Mary Coool Mary Coool Mary Mary | (R)- (+)-2-methyl-2-[4-{3-(5-methanesulfonyloxyindol-1-yl) propyl} phenoxy] butanoic acid, Arginine salt |
| Me-stood NH2 | (S)- (-)-2-methyl-2-[4-{3-(5-methanesulfonyloxyindol-1-yl) propyl} phenoxy] butanoic acid, Arginine salt |
| Me, O CO2H O CO2H NH2N H NH2 NH2 | 2-methyl-2- [4-{3-(5- methanesulfonyloxyindol-1-yl) propyl} phenoxy] propanoic acid Arginine salt |
| Me ² s ^c O N O CO2H NH2 CO3H NH2 | 2-methyl-2- [3-{3-(5-methanesulfonyloxyindol-1-yl) propyl} phenoxy] propanoic acid Arginine salt |
| Me, s, °° | 2-Methyl-2-[4-{4-(5-methane sulfonyloxyindol-1yl)butyl} phenoxy]propanoic acid, arginine salt |
| 0,5,0 CO2 M2N NH2 COOH NH2 COOH NH2 | 2-Methyl-2-[3-{3-(5-(para-toluenesulfonyloxy)indol-1-yl)propyl} phenoxy] propanoic acid, arginine salt |
| Me, S, O, | 2-[3-{3-(5- Methanesulfonyloxyindol-1- yl)propyl}phenoxy]propanoic acid, arginine |

| Me COOH HAN THE COOH NH4 OF ON THE COOH NH4 NH4 NH4 NH4 | 1-[4-{4-(5-methanesulfonyloxyindol-1-yl)butyl}phenoxy]cyclopentane-1- |
|--|---|
| | carboxylic acid, arginine salt |

| Structure | IUPAC Name |
|---|--|
| Mg ² · Me, s, O, | 1-[4-{3-(5- methanesulfonyloxyindol-1- yl)propyl}phenoxy]cyclohexane-1- carboxylic acid, magnesium salt |
| Mg ² · Me, co, co, co, co, co, co, co, co, co, co | 1-[4-{3-(5- Methanesulfonyloxyindol-1- yl)propyl}phenoxy]cyclopentane-1- carboxylic acid, magnesium salt |
| Mg²* | (racemic) Methyl-2-methyl-2-[4-{3- (5-methanesulfonyloxyindol-1-yl) propyl} phenoxy] butanoic acid Magnesium salt |

| Structure | IUPAC Name |
|---|--|
| Mg ² · Me co | 1-[4-{3-(7-Methanesulfonyloxy-3, 4-dihydro-2 <i>H</i> -bezo [<i>b</i>] [1, 4] oxazin- 4-yl)propyl}phenoxy]cyclopentane- 1-carboxylic acid, magnesium salt |
| May COOH NH3 | 2-Methyl-2-[4-{4-(7-methanesulfonyloxy-3, 4-dihydro-2 <i>H</i> -bezo [<i>b</i>] [1, 4] oxazin-3-on-4-yl)butyl}phenoxy]propanoic acid, Arginine salt |
| H ₂ N H ₂ CO ₂ H NH ₂ O O O O O NH ₂ | 2-methyl-2- [4-{3-(3,4-dihydro-2H-bezo [b][1,4] 0xazin-4-yl) propyl} phenoxy] propanoic acid Arginine salt |

| H ₃ C ₁ S ₂ O ₂ C ₃ | 2-Methyl-2-[3-{3-(7- Methanesulfonyloxy-3, 4-dihydro- 2 <i>H</i> -bezo [<i>b</i>] [1, 4] oxazin-4-yl) propyl} phenoxy] propanoic acid, Arginine salt |
|---|--|
|---|--|

| Structure | IUPAC Name |
|--|--|
| 0; co cos o nh3 | 2-Methyl-2-[4-{3-(3- methanesulfonyloxyphenoxy) propyl} phenoxy] propanoic acid Arginine salt |
| H ₂ N ₂ COOH NH ₂ NH ₃ NH ₃ | 2-Methyl-2-[4-{4-(4- methanesulfonyloxyphenoxy)butyl} phenoxy]propanoic acid, arginine salt |
| H ₂ N | 2-Methyl-2-[3-{5-(4-methanesulfonyloxyphenoxy)pentyl} phenoxy]propanoic acid, arginine salt |

62. A process for the preparation of compound of formula (I),

$$Ar_1 \qquad Y \qquad A \qquad (CH_2)_m \qquad R^6 \qquad (CH_2)_n \qquad COOR^7$$
(I)

wherein Ar₁ represents

and all other symbols are as defined above, which process comprises, reacting compound of formula (8)

wherein Ar₁ represents

with a compound of formula (9)

$$L^{3} \longrightarrow Y \longrightarrow A \longrightarrow (CH_{2})_{m} \longrightarrow R^{6} \longrightarrow (CH_{2})_{n} \longrightarrow COOR^{7}$$

$$(9)$$

where L³ represents a leaving group selected from halo or mesyloxy, and all other symbols have the meaning as described above.

63. A pharmaceutical composition, which comprises a compound of formula (I)

$$Ar_1 \longrightarrow Y \longrightarrow A \longrightarrow (CH_2)_m \longrightarrow (CH_2)_m \longrightarrow COOR^7 \qquad (I)$$

as defined in claim 1 and a pharmaceutically acceptable carrier, diluent, excipient or solvate.

64. The pharmaceutical composition of claim 63, wherein the compound is as claimed in claims 30.

- 65. The pharmaceutical composition of claim 63, wherein the compound is as claimed in claims 38.
- 66. The pharmaceutical composition of claim 63, wherein the compound is as claimed in claims 41.
- 67 The pharmaceutical composition of claim 63, wherein the compound is as claimed in claims 43.
- 68. The pharmaceutical composition of claim 63, wherein the compound is as claimed in claims 49.
- 69. The pharmaceutical composition of claim 63, wherein the compound is as claimed in claims 51.
- 70. A pharmaceutical composition as claimed in claim 63, in the form of a tablet, capsule, powder, syrup, solution or suspension.
- 71. A method for treating and/or preventing dyslipidemia comprising administering a compound of formula (I) as defined in claim 1 or a pharmaceutical composition according to claim 63 to a patient in need thereof.
- 72. A method for treating and/or preventing diabetes caused by insulin resistance or impaired glucose tolerance comprising administering a compound of formula (I) as defined in claim 1 or a pharmaceutical composition according to claim 63 to a patient in need thereof.
- 73. Use of a compound of formula (I) as defined in claim 1 or a pharmaceutical composition according to claim 63 for treating and/or preventing dyslipidemia.
- 74. Use of a compound of formula (I) as defined in claim 1 or a pharmaceutical composition according to claim 63 for treating and/or preventing diabetes caused by insulin resistance or impaired glucose tolerance.

- 75. A medicine for treating and/or preventing diabetes caused dyslipidemia comprising administering a compound of formula (I) as defined in claim 1 or a pharmaceutical composition according to claim 63 to a patient in need thereof.
- 76. A medicine for treating and/or preventing diabetes caused by insulin resistance or impaired glucose tolerance comprising administering a compound of formula (I) as defined in claim 1 or a pharmaceutical composition according to claim 63 to a patient in need thereof.